Intracellular tumor antigens presented on the cell surface in the context of human leukocyte antigen (HLA) molecules have been targeted by T cell–based therapies, but there has been little ...

"This is a new approach for attacking WT1, an important cancer target, with an antibody therapy. This is something that was previously not possible," said David A. Scheinberg, MD, PhD, Chair of ...

In just one year since the start of the collaboration, the companies have identified a WT1/HLA-A02-specific T cell engager (WT1xCD3x4-1BB tri-specific antibody) with outstanding preclinical anti ...

Samples were incubated overnight at 4 °C with antibodies to Wt1 (1:800; C19, Santa Cruz Biotechnology) or GFP (1:800; Abcam) diluted with 0.1% BSA and 0.3% Triton X-100 in PBS (pH 7.4), followed ...

Early results of a trial to treat leukaemia with a WT1 DNA vaccine, has shown robust vaccine-specific antibody responses in all vaccinated patients evaluated to date. Furthermore, T cell immune ...

In the new study, a monoclonal antibody, called ESK1, targets a protein associated with many types of cancer. The targeted protein, called WT1, is over-produced in a range of leukemias and other ...

In a study published today in an Advance Online paper in Nature Biotechnology, the TSRI scientists screened a library of 100 million antibodies ... the restraints on WT1, a transcription factor ...

Unlike other human therapeutic monoclonal antibodies, which can only target proteins that remain on the outside of cancer cells, ESK1 targets WT1, a protein that resides on the inside of the cell.

Indeed, WT1 antibody therapies are showing promise in clinical trials for lung cancer, leukaemia, and other malignancies. Despite its emergence as a significant target in cancer therapy, our ...

"This is a new approach for attacking WT1, an important cancer target, with an antibody therapy. This is something that was previously not possible," said David A. Scheinberg, MD, PhD, Chair of ...